Development of drug resistance has considerably limited the efficacy of cancer treatments,
including chemotherapy and targeted therapies. Hence, understanding the molecular …

Summary Angiopoietin-2 (ANG2/ANGPT2) is a context-dependent TIE2 receptor
agonist/antagonist and proangiogenic factor. Although ANG2 neutralization improves tumor …

Antiangiogenic tumor therapy has failed in the adjuvant setting. Here we show that inhibition
of the Tie2 ligand angiopoietin-2 (Ang2) effectively blocks metastatic growth in preclinical …

Purpose: Vanucizumab is an investigational antiangiogenic, first-in-class, bispecific mAb
targeting VEGF-A and angiopoietin-2 (Ang-2). This first-in-human study evaluated the safety …

First-line chemotherapy+ bevacizumab (BEV) is one of the standards of care in advanced
colorectal cancer (CRC). Contrary to anti-EGFR agents, it is currently not possible to identify …

Angiopoietin‐2 (ANGPT2) is a prognostic factor in metastatic colorectal cancer (CRC).
Nevertheless, it remains to be elucidated which molecular characteristics make up the …

Purpose Angiopoietin-2 (Ang-2) has been proven to be a potential agent for malignant
cancer treatment. The aim of the current study was to investigate the inhibitory effects of …

Vascular endothelial growth factor (VEGF) inhibition by the addition of bevacizumab to the
chemotherapy regimen of metastatic colorectal cancer leads to an improved outcome …

Purpose The purpose of this study was to compare the efficacy and safety of a proposed
bevacizumab biosimilar to those of the reference product in patients with metastatic …

The growth factors derived from the microenvironment create an environment conducive to
tumor growth and survival. HGF deprivation using neutralizing antibody enhanced …